Navigation Links
Delcath Signs Agreement With Synerx and Mylan's Bioniche Teoranta for Melphalan Supply
Date:10/14/2010

A filing during the fourth quarter of 2010."

About Delcath Systems

Delcath Systems, Inc. is a development stage, specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath  concluded a Phase III metastatic melanoma study, and the Company recently  completed a multi–arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, our ability to successfully complete an FDA New Drug Application (NDA) during the fourth quarter of 2010, benefits to our NDA submission to the FDA from the Synerx/Bioniche agreement, if any, acceptance of the new drug application by the FDA, approval by the FDA or other regulatory authorities of the current or future drug delivery system for the treatment of metastatic melanoma, the future  reliability of melphalan supply for the U.S. market, our ability to successfully complete other clinical trials and secure regulatory approval of our c
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014 The Parenteral Drug Association ... global post-approval changes protocols. The new ... topic expressed by industry participants and regulatory authority representatives ... month in Washington, DC . Representatives ... hand for the workshop. Attendees indicated openness to engaging ...
(Date:9/19/2014)... DALLAS , Sept. 19, 2014 ... Market Outlook to 2020″, provides key ... General Surgery devices market. The report ... dollars, and volume (in units) within ... Cystoscopes, Colonoscopes, Sigmoidoscopes, Esophagoscopes & Gastroscopes, ...
(Date:9/19/2014)... 19, 2014  The board of directors of AbbVie ... cash dividend of $0.42 per share.  ... stockholders of record at the close of business on ... a global, research-based biopharmaceutical company formed in 2013 following ... its expertise, dedicated people and unique approach to innovation ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... , the leader in heart rate monitoring and fitness assessment ... Rate Technology Supplier" for U.S. Soccer through 2013.  ... major national and international events, including the London 2012 Olympic ... be used to help these nine National Teams gain a ...
... Feb. 29, 2012  Four Rivers Software Systems, Inc. the ... to the healthcare industry, is pleased to announce ... part of this critical release, we have included ... that will benefit users.  The ...
Cached Medicine Technology:Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 2Polar Named Official Heart Rate Technology Supplier of U.S. Soccer Federation 3Four Rivers Software Systems Launches TMS 2012.5.5 2
(Date:9/19/2014)... who live in leafy, green neighborhoods are less likely to ... suggests. Researchers analyzed data from more than 64,000 births ... in a neighborhood with plenty of trees, grass and other ... birth (before 30 weeks) and a 13 percent lower risk ... born to mothers who lived in greener neighborhoods were also ...
(Date:9/19/2014)... U.S. Food and Drug Administration approved a new type 2 ... class of once-a-week injectable drugs that help manage blood sugar ... is a new treatment option, which can be used alone ... levels in the overall management of type 2 diabetes," Dr. ... Evaluation II, said in an agency news release. ...
(Date:9/19/2014)... Washington, DC (PRWEB) September 19, 2014 ... announced an important partnership with the National Fire ... fire safety. The collaboration, formalized today in a ... empower Alliance Members, factories, workers and other stakeholders ... that will help protect the health and safety ...
(Date:9/19/2014)... MetroMD, a leading anti-ageing clinic has called its HGH ... therapy has grown tremendously across USA in the last decade ... dependable. It has far reaching benefits for ageing men and ... healthy and active lifestyle even beyond their middle age. ... at MetroMD said, “HGH or Human Growth hormones are the ...
(Date:9/19/2014)... September 19, 2014 "I have difficulty ... wrinkles due to stretching the skin around my eyes ... "This inspired me to design a more convenient method ... LENS SYSTEM provides a quicker, easier, more sanitary method ... to perform this task manually, saves time and effort, ...
Breaking Medicine News(10 mins):Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 2Health News:Alliance for Bangladesh Worker Safety and NFPA Sign Memorandum of Understanding to Strengthen Safety in Bangladesh Garment Factories 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... Company Locations in Alabama, Georgia, Indiana, Iowa, Kansas, ... Texas, Virginia and WisconsinWASHINGTON, Jan. 15 SouthernCare ... the United States a total of $24.7 million ... submitted false claims to the government for patients ...
... coalition of clergy and lay members from faith organizations throughout ... Senator Richard Burr to end his opposition to legislation that ... over tobacco products. The legislation would protect kids from ... to filibuster the legislation if it was brought to the ...
... required for foods from these animals, agency says , , ... and Drug Administration on Thursday issued its final regulations ... rules do not require consumer labeling for foods from ... (rDNA) to introduce new characteristics or traits into an ...
... 15 Boston Scientific Corporation (NYSE: BSX ) today ... Circuit. The case involves a Boston Scientific patent, which in ... the decision, the Court found that the patent was invalid as ... by Johnson and Johnson of a 2005 jury verdict in the ...
... of Trade Alerts on stocks making news today. Investors can ... visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: Eli Lily ... (NYSE: PCS ), ConAgra Foods Inc. (NYSE: ... ), Target Corp. (NYSE: TGT ) and Dow ...
... around 50 percent, despite proven benefits, report says , , THURSDAY, ... colon cancer saves lives, but too few Americans are getting ... report shows. , The rate of screening for breast and ... the rate of colorectal cancer screening has increased but not ...
Cached Medicine News:Health News:Alabama-Based Hospice Company Pays U.S. $24.7 Million to Settle Health Care Fraud Claims 2Health News:North Carolina Faith Leaders Call on Sen. Burr to End Filibuster Threat of Legislation to Protect Kids From Tobacco 2Health News:North Carolina Faith Leaders Call on Sen. Burr to End Filibuster Threat of Legislation to Protect Kids From Tobacco 3Health News:FDA Issues Final Regulations for Genetically Engineered Animals 2Health News:FDA Issues Final Regulations for Genetically Engineered Animals 3Health News:Boston Scientific Announces Court Decision 2Health News:Boston Scientific Announces Court Decision 3Health News:Beacon Equity Issues Technical Trade Alerts on Headline Stocks: LLY, PCS, CAG, FRX, TGT, DOW 2Health News:More Americans Urged to Get Cancer Screenings 2Health News:More Americans Urged to Get Cancer Screenings 3
BD Vacutainer® Heparin Tubes are spray-coated with either lithium heparin or sodium heparin and are used for plasma determinations in chemistry....
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... are available in two versions. ... a clotting activator and is ... serum is required for testing ... is suitable where the testing ...
Medicine Products: